MA-BATTERY-VENTURES
27.6.2024 13:01:33 CEST | Business Wire | Press release
Battery Ventures, a global, technology-focused investment firm, today announced six new internal promotions across three offices, including the elevation of Satoshi Harris-Koizumi to partner and Collier Searle to principal.
Harris-Koizumi is based in New York and focuses on later-stage and majority software investments, mainly in the U.S. Since joining Battery 12 years ago, he has supported technology companies transforming industries ranging from hospitality to manufacturing to engineering and supply chain, among others.
Specifically, Harris-Koizumi has worked with exited Battery software companies Cambrio (a CAD/CAM specialist, acquired by Sandvik); HighJump (supply-chain tech, acquired by Accellos); Mendix (low-code platform technology, acquired by Siemens); and Olo (restaurant-ordering software, NYSE: OLO). He is currently involved with Battery’s investments in product-content software company 1WorldSync; developer-tools software firm AdaCore; club/member-management software company Clubessential Holdings; restaurant-software provider Crunchtime; translation-software company Smartling; and engineering-design software firm Tech Soft 3D. Harris-Koizumi, known as Toshi, holds a BA in economics from Dartmouth.
Searle, also based in New York, joined Battery in 2020 and focuses on late-stage and buyout investments in Europe and the U.S. She is involved with Battery’s investments in ORTEC, a company based in the Netherlands which provides decision-support software and data-science capabilities, and Shiftmove, a Berlin-based company providing “mobility-management” solutions to enterprises. Battery formed Shiftmove last year after acquiring two complementary, European fleet-management companies, Vimcar and Avrios. Before Battery, Searle worked at Apax Partners and Bank of America Merrill Lynch. She holds a BA in philosophy and political science from Middlebury.
“We are extremely excited to promote Toshi to partner and Collier to principal,” said Morad Elhafed, a Battery general partner who works closely with both investors. “Toshi has distinguished himself both by sourcing key deals for the firm—including Cambrio, Clubessential, Mendix and Tech Soft—and, later, serving as a trusted advisor to our portfolio executives and helping their companies scale. Similarly, Collier has done outstanding sourcing and advisory work, particularly as we increase our buyout activity in Europe. We are excited for both of them to continue their careers at Battery and add more value to the firm as we move into our fifth decade of investing.”
Battery also named two new vice presidents, Max Jessen and Stefan Momic, and two new associates, Jack McGuinness and Grace Hermes. Jessen and Momic are both based in Boston and work in Battery’s growing industrial technology and life-science tools practice. McGuinness, based in London, also focuses on industrial technology and life-science tools, while Hermes works in Battery’s New York office and focuses on later-stage software investments.
Earlier this year, Battery also announced the promotions of Aaron Neil to vice president and Luis-Luca de Haas to associate. In addition, Matt Penney was promoted to partner, information technology.
Battery Ventures provides investment advisory services solely to privately offered funds. Battery Ventures neither solicits nor makes its services available to the public or other advisory clients. For more information about Battery Ventures’ potential financing capabilities for prospective portfolio companies, please refer to our website. For a complete list of portfolio companies, please click here.
About Battery
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, consumer tech, healthcare IT and industrial technology and life-science tools. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from offices in Boston, San Francisco, Menlo Park, New York, London, and Tel Aviv. Follow the firm on X @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627095034/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Huawei, LG Electronics and Nokia Named as Founder Licensors of New Sisvel POS Pool1.4.2026 12:17:00 CEST | Press release
Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today. Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology. Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch. Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering. Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programm
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 11:11:00 CEST | Press release
- Medical oncologist and accomplished clinical leader brings deep development and industry experience to Mosaic’s Executive Leadership team - Vince will lead research and development for Mosaic’s drug combination programs, including the build-out of the Company’s early pipeline Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechno
The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 09:00:00 CEST | Press release
New One-Day Intensive Experience Offered 9 June Ahead of Conference 10-11 June at Tobacco Dock Featuring 10 Stages and 14 Tracks The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights
Samsung Research Reveals Over Half of Europeans Admit to Looking at a Stranger's Phone Screen in Public – With Nearly a Quarter Doing so out of Sheer Curiosity1.4.2026 08:00:00 CEST | Press release
From dating apps to financial details, respondents report seeing a wide range of highly personal information on others' screens 56% of people admit to having looked at strangers’ phone screens accidentally, whereas 24% have done so out of curiosity. 57% identify public transport as the most likely place to notice someone else's screen. While 48%* feel confident they can keep their phone activity private when using it in crowded places, another 52%** acknowledge it is easy to see someone’s screen who is next to you in a public place without trying to look. 33% say they have seen personal content on a stranger’s phone in public. Some smartphone users who have looked at a stranger’s phone screen in public ignore and continue what they were doing (28%) or look away immediately (27%), but others (7%) admit to continuing to look discreetly. The new Samsung Galaxy S26 Privacy Display1 limits side-angle viewing of your screen to protect your privacy in any setting. As millions of Europeans2 ge
RevolKa Reimagines Antibody Engineering with "RevoAb®"1.4.2026 06:30:00 CEST | Press release
A Same-day Sequence Optimization Service to Elevate Antibody Expression Levels by RevolKa’s advanced AI Protein Engineering Engine RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibodyyields. RevoAb®:The Next-Gen AI Antibody Design Since December 2023, RevolKa has provided an antibody optimization services utilizing aiProtein®. The newly launched RevoAb® is a quick intuitive online antibody sequence optimization service that integrates RevolKa’s core technology—the "Refined Naturalness Framework Engineering". RevoAb® is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially protein expression levels, without trade-off of affinity. This allo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom